None listed
Conditions
Brief summary
We evaluated the efficacy and safety of ropivacaine continuous infusion (Painbuster) in liver donors compared to intrathecal morphine (ITM) with intravenous patient controlled analgesia (IV PCA). Adult donors were randomly allocated into 2 groups: ITM + IV PCA group, Painbuster + rescue IV PCA group. Donors in Painbuster + rescue IV PCA group were placed a catheter in the wound and 0.5% ropivacaine was infused for postoperative 72 hours at a rate of 4ml/hr. Donors in ITM + IV PCA group received morphine sulfate (400ug) and fentanyl IV PCA postoperatively . The visual analogue scale (VAS) at rest and coughing, and IV PCA fentanyl and meperidine consumptions were assessed for 72 hours postoperatively. Side effects including sedation, dizziness, nausea, vomiting, pruritis, respiratory depression, wound seroma or hematoma, and bowel recovery time were recorded.
Interventions
Local anesthetic (0.5% Ropivacaine) wound instillation device, Painbuster 4ml/hr, for postoperative 72 hours
Painbuster is an elastometric pump with catheters that have multiorifice holes through which local anesthetics can be delivered at a constant rate 4ml/hr if the catheters are placed at the wound are.
As for a rescue analgesics, fentanyl intravenous patient controlled analgeisa (IV PCA) was applied at the end of surgery with a regimen of 1500 ug of fentanyl in normal saline 100 mL (15
Local anesthetic (0.5% Ropivacaine) wound instillation device, Painbuster 4ml/hr, for postoperative 72 hours Painbuster is an elastometric pump with catheters that have multiorifice holes through which local anesthetics can be delivered at a constant rate 4ml/hr if the catheters are placed at the wound are. As for a rescue analgesics, fentanyl intravenous patient controlled analgeisa (IV PCA) was applied at the end of surgery with a regimen of 1500 ug of fentanyl in normal saline 100 mL (15 ug/mL), programmed for 1ml bolus, 15 minutes lockout time without a basal infusion.
Sponsors
Soo Joo Choi
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
All living liver donors
Exclusion criteria
A known allergy to eggs, propofol or any of the drugs used in the study. Bleeding diathesis, neurologic dysfunction (preexisting lower limb neurological deficit), recent systemic or local infections, insufficient comprehension to use the PCA device, history of drug use, or under treatment with opioids because of chronic pain.
Outcome results
None listed